Carboprost Tromethamine for Fibroid Tumor

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Northwestern University - Northwestern Medicine, Lavin Family Pavilion, Chicago, IL
Fibroid Tumor+4 More
Carboprost Tromethamine - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).

Eligible Conditions

  • Gynecologic Diseases
  • Fibroid Tumor
  • Fibroid Uterus

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Fibroid Tumor

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Through study completion, up to 2 years

Month 1
Does instillation of low-dose carboprost facilitate complete resection of FIGO II fibroids during hysteroscopic resection?
Year 2
To quantitatively assess the efficiency of fibroid resection after carboprost administration by analyzing the video recording from surgery

Trial Safety

Safety Progress

1 of 3

Other trials for Fibroid Tumor

Trial Design

1 Treatment Group

Hemabate
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Carboprost Tromethamine · No Placebo Group · Phase < 1

Hemabate
Drug
Experimental Group · 1 Intervention: Carboprost Tromethamine · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, up to 2 years
Closest Location: Northwestern University - Northwestern Medicine, Lavin Family Pavilion · Chicago, IL
Photo of Chicago 1Photo of Chicago 2Photo of Chicago 3
N/AFirst Recorded Clinical Trial
0 TrialsResearching Fibroid Tumor
0 CompletedClinical Trials

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,421 Previous Clinical Trials
717,347 Total Patients Enrolled
Magdy p Milad, MD, MSPrincipal InvestigatorNorthwestern University, Northwestern Memorial Hopsital

Eligibility Criteria

Age 18+ · Female Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.